Oral Contraceptives in Polycystic Ovary Syndrome: Risk-Benefit Assessment

ABSTRACT

Combined oral contraceptive pills (OCPs) have been a key component of the chronic treatment of polycystic ovary syndrome (PCOS) by improving androgen excess and regulating menstrual cycles. Earlier epidemiologic studies with second- and third-generation OCPs in the general population have raised important questions regarding long-term cardiometabolic effects of these agents. In PCOS, there are only a few short-term studies with contradictory results evaluating potential adverse effects of OCPs on cardiovascular risk factors and glucose homeostasis. These studies included a small number of participants and did not take into account several confounding factors that might influence the outcome. Nevertheless, limited available data support the benefits of long-term OCP use in PCOS. By contrast, solid evidence for cardiometabolic adverse outcome with the use of these agents, especially with newer OCPs containing antiandrogenic progestins, is lacking. More studies are needed to resolve controversies regarding the safety of long-term OCP use in PCOS. Meanwhile, assessment of each PCOS patient's personal cardiometabolic risk profile should be an essential component of the evaluation before prescribing OCPs and also during follow-up.

KEYWORDS

Androgen excess - metabolic risk - insulin - thrombosis - oral contraceptive - cyproterone acetate - drospirenone - dienogest

REFERENCES

• 1 Ehrmann D A. Polycystic ovary syndrome.  N Engl J Med. 2005;  352 1223-1236
• 2 Yildiz B O. Recent advances in the treatment of polycystic ovary syndrome.  Expert Opin Investig Drugs. 2004;  13 1295-1305
• 3 Vrbikova J, Cibula D. Combined oral contraceptives in the treatment of polycystic ovary syndrome.  Hum Reprod Update. 2005;  11 277-291
• 4 Diamanti-Kandarakis E, Baillargeon J P, Iuorno M J, Jakubowicz D J, Nestler J E. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral contraceptive pills.  J Clin Endocrinol Metab. 2003;  88 1927-1932
• 5 Nader S, Diamanti-Kandarakis E. Polycystic ovary syndrome, oral contraceptives and metabolic issues: new perspectives and a unifying hypothesis.  Hum Reprod. 2007;  22 317-322
• 6 Petitti D B. Clinical practice. Combination estrogen-progestin oral contraceptives.  N Engl J Med. 2003;  349 1443-1450
• 7 Sitruk-Ware R. New progestagens for contraceptive use.  Hum Reprod Update. 2006;  12 169-178
• 8 Stanczyk F Z. All progestins are not created equal.  Steroids. 2003;  68 879-890
• 9 Elger W, Beier S, Pollow K, Garfield R, Shi S Q, Hillisch A. Conception and pharmacodynamic profile of drospirenone.  Steroids. 2003;  68 891-905
• 10 Boyce J, Fawcett J W, Noall E W. Coronary thrombosis and Conovide.  Lancet. 1963;  1 111
• 11 Jick H, Dinan B, Herman R, Rothman K J. Myocardial infarction and other vascular diseases in young women. Role of estrogens and other factors.  JAMA. 1978;  240 2548-2552
• 12 Stadel B V. Oral contraceptives and cardiovascular disease (first of two parts).  N Engl J Med. 1981;  305 612-618
• 13 Walker I D. Exogenous sex hormones and thrombophilia.  Obstet Gynecol Clin North Am. 2006;  33 467-479 x
• 14 World Health Organization Collaborative Study of Cardiovascular Disease and Steroid Hormone Contraception . Venous thromboembolic disease and combined oral contraceptives: results of international multicentre case-control study.  Lancet. 1995;  346 1575-1582
• 15 Crook D. Do different brands of oral contraceptives differ in their effects on cardiovascular disease?.  Br J Obstet Gynaecol. 1997;  104 516-520
• 16 Khader Y S, Rice J, John L, Abueita O. Oral contraceptives use and the risk of myocardial infarction: a meta-analysis.  Contraception. 2003;  68 11-17
• 17 Baillargeon J P, McClish D K, Essah P A, Nestler J E. Association between the current use of low-dose oral contraceptives and cardiovascular arterial disease: a meta-analysis.  J Clin Endocrinol Metab. 2005;  90 3863-3870
• 18 Merz C N, Johnson B D, Berga S, Braunstein G, Reis S E, Bittner V. Past oral contraceptive use and angiographic coronary artery disease in postmenopausal women: data from the National Heart, Lung, and Blood Institute-sponsored Women's Ischemia Syndrome Evaluation.  Fertil Steril. 2006;  85 1425-1431
• 19 Sidney S, Siscovick D S, Petitti D B et al.. Myocardial infarction and use of low-dose oral contraceptives: a pooled analysis of 2 US studies.  Circulation. 1998;  98 1058-1063
• 20 Schwartz S M, Siscovick D S, Longstreth Jr W T et al.. Use of low-dose oral contraceptives and stroke in young women.  Ann Intern Med. 1997;  127 596-603
• 21 Petitti D B, Sidney S, Bernstein A, Wolf S, Quesenberry C, Ziel H K. Stroke in users of low-dose oral contraceptives.  N Engl J Med. 1996;  335 8-15
• 22 Schwingl P J, Ory H W, Visness C M. Estimates of the risk of cardiovascular death attributable to low-dose oral contraceptives in the United States.  Am J Obstet Gynecol. 1999;  180 241-249
• 23 Godsland I F. The influence of female sex steroids on glucose metabolism and insulin action.  J Intern Med Suppl. 1996;  738 1-60
• 24 Godsland I F, Crook D, Simpson R et al.. The effects of different formulations of oral contraceptive agents on lipid and carbohydrate metabolism.  N Engl J Med. 1990;  323 1375-1381
• 25 Godsland I F, Walton C, Felton C, Proudler A, Patel A, Wynn V. Insulin resistance, secretion, and metabolism in users of oral contraceptives.  J Clin Endocrinol Metab. 1992;  74 64-70
• 26 Watanabe R M, Azen C G, Roy S, Perlman J A, Bergman R N. Defects in carbohydrate metabolism in oral contraceptive users without apparent metabolic risk factors.  J Clin Endocrinol Metab. 1994;  79 1277-1283
• 27 Troisi R J, Cowie C C, Harris M I. Oral contraceptive use and glucose metabolism in a national sample of women in the United States.  Am J Obstet Gynecol. 2000;  183 389-395
• 28 Kim C, Siscovick D S, Sidney S, Lewis C E, Kiefe C I, Koepsell T D. Oral contraceptive use and association with glucose, insulin, and diabetes in young adult women: the CARDIA Study. Coronary Artery Risk Development in Young Adults.  Diabetes Care. 2002;  25 1027-1032
• 29 Rimm E B, Manson J E, Stampfer M J et al.. Oral contraceptive use and the risk of type 2 (non-insulin-dependent) diabetes mellitus in a large prospective study of women.  Diabetologia. 1992;  35 967-972
• 30 Chasan-Taber L, Willett W C, Stampfer M J et al.. A prospective study of oral contraceptives and NIDDM among U.S. women.  Diabetes Care. 1997;  20 330-335
• 31 Kjos S L, Peters R K, Xiang A, Thomas D, Schaefer U, Buchanan T A. Contraception and the risk of type 2 diabetes mellitus in Latina women with prior gestational diabetes mellitus.  JAMA. 1998;  280 533-538
• 32 Grimes D A, Economy K E. Primary prevention of gynecologic cancers.  Am J Obstet Gynecol. 1995;  172 227-235
• 33 The ESHRE Capri Workshop Group . Noncontraceptive health benefits of combined oral contraception.  Hum Reprod Update. 2005;  11 513-525
• 34 Gallo M F, Lopez L M, Grimes D A, Schulz K F, Helmerhorst F M. Combination contraceptives: effects on weight.  Cochrane Database Syst Rev. 2006;  CD003987
• 35 World Health Organization .Medical eligibility criteria for contraceptive use. Third edition. 2004 Available at: http://www.who.int/reproductive-health/publications/mec/index.htm
• 36 Cerel-Suhl S L, Yeager B F. Update on oral contraceptive pills.  Am Fam Physician. 1999;  60 2073-2084
• 37 Mastorakos G, Koliopoulos C, Creatsas G. Androgen and lipid profiles in adolescents with polycystic ovary syndrome who were treated with two forms of combined oral contraceptives.  Fertil Steril. 2002;  77 919-927
• 38 Falsetti L, Gambera A, Tisi G. Efficacy of the combination ethinyl oestradiol and cyproterone acetate on endocrine, clinical and ultrasonographic profile in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 36-42
• 39 Belisle S, Love E J. Clinical efficacy and safety of cyproterone acetate in severe hirsutism: results of a multicentered Canadian study.  Fertil Steril. 1986;  46 1015-1020
• 40 Miller J A, Wojnarowska F T, Dowd P M et al.. Anti-androgen treatment in women with acne: a controlled trial.  Br J Dermatol. 1986;  114 705-716
• 41 Mowszowicz I, Wright F, Vincens M et al.. Androgen metabolism in hirsute patients treated with cyproterone acetate.  J Steroid Biochem. 1984;  20 757-761
• 42 Oelkers W. Drospirenone, a progestogen with antimineralocorticoid properties: a short review.  Mol Cell Endocrinol. 2004;  217 255-261
• 43 Guido M, Romualdi D, Giuliani M et al.. Drospirenone for the treatment of hirsute women with polycystic ovary syndrome: a clinical, endocrinological, metabolic pilot study.  J Clin Endocrinol Metab. 2004;  89 2817-2823
• 44 Palep-Singh M, Mook K, Barth J, Balen A. An observational study of Yasmin in the management of women with polycystic ovary syndrome.  J Fam Plann Reprod Health Care. 2004;  30 163-165
• 45 Azziz R, Waggoner W T, Ochoa T, Knochenhauer E S, Boots L R. Idiopathic hirsutism: an uncommon cause of hirsutism in Alabama.  Fertil Steril. 1998;  70 274-278
• 46 Hardiman P, Pillay O C, Atiomo W. Polycystic ovary syndrome and endometrial carcinoma.  Lancet. 2003;  361 1810-1812
• 47 Apridonidze T, Essah P A, Iuorno M J, Nestler J E. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2005;  90 1929-1935
• 48 Ehrmann D A, Liljenquist D R, Kasza K, Azziz R, Legro R S, Ghazzi M N. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2006;  91 48-53
• 49 Legro R S. Polycystic ovary syndrome and cardiovascular disease: a premature association?.  Endocr Rev. 2003;  24 302-312
• 50 Orio F, Palomba S, Colao A. Cardiovascular risk in women with polycystic ovary syndrome.  Fertil Steril. 2006;  86(Suppl 1) S20-S21
• 51 Christian R C, Dumesic D A, Behrenbeck T, Oberg A L, Sheedy II P F, Fitzpatrick L A. Prevalence and predictors of coronary artery calcification in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 2562-2568
• 52 Rizzo M, Rini G B, Carmina E. Androgen excess and cardiovascular risk.  Minerva Endocrinol. 2007;  32 67-71
• 53 Chang W Y, Knochenhauer E S, Bartolucci A A, Azziz R. Phenotypic spectrum of polycystic ovary syndrome: clinical and biochemical characterization of the three major clinical subgroups.  Fertil Steril. 2005;  83 1717-1723
• 54 Yildiz B O, Gedik O. Insulin resistance in polycystic ovary syndrome: hyperandrogenemia versus normoandrogenemia.  Eur J Obstet Gynecol Reprod Biol. 2001;  100 62-66
• 55 Solomon C G, Hu F B, Dunaif A et al.. Menstrual cycle irregularity and risk for future cardiovascular disease.  J Clin Endocrinol Metab. 2002;  87 2013-2017
• 56 Dunaif A. Insulin resistance and the polycystic ovary syndrome: mechanism and implications for pathogenesis.  Endocr Rev. 1997;  18 774-800
• 57 Ovalle F, Azziz R. Insulin resistance, polycystic ovary syndrome, and type 2 diabetes mellitus.  Fertil Steril. 2002;  77 1095-1105
• 58 Azziz R, Carmina E, Dewailly D et al.. Positions statement: criteria for defining polycystic ovary syndrome as a predominantly hyperandrogenic syndrome: an Androgen Excess Society guideline.  J Clin Endocrinol Metab. 2006;  91 4237-4245
• 59 Ehrmann D A, Barnes R B, Rosenfield R L, Cavaghan M K, Imperial J. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome.  Diabetes Care. 1999;  22 141-146
• 60 Legro R S, Kunselman A R, Dodson W C, Dunaif A. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective, controlled study in 254 affected women.  J Clin Endocrinol Metab. 1999;  84 165-169
• 61 Weerakiet S, Srisombut C, Bunnag P, Sangtong S, Chuangsoongnoen N, Rojanasakul A. Prevalence of type 2 diabetes mellitus and impaired glucose tolerance in Asian women with polycystic ovary syndrome.  Int J Gynaecol Obstet. 2001;  75 177-184
• 62 Gambineri A, Pelusi C, Manicardi E et al.. Glucose intolerance in a large cohort of mediterranean women with polycystic ovary syndrome: phenotype and associated factors.  Diabetes. 2004;  53 2353-2358
• 63 Norman R J, Masters L, Milner C R, Wang J X, Davies M J. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome.  Hum Reprod. 2001;  16 1995-1998
• 64 American Diabetes Association . Screening for diabetes.  Diabetes Care. 2002;  25 S21-S24
• 65 Korytkowski M T, Mokan M, Horwitz M J, Berga S L. Metabolic effects of oral contraceptives in women with polycystic ovary syndrome.  J Clin Endocrinol Metab. 1995;  80 3327-3334
• 66 Nader S, Riad-Gabriel M G, Saad M F. The effect of a desogestrel-containing oral contraceptive on glucose tolerance and leptin concentrations in hyperandrogenic women.  J Clin Endocrinol Metab. 1997;  82 3074-3077
• 67 Dahlgren E, Landin K, Krotkiewski M, Holm G, Janson P O. Effects of two antiandrogen treatments on hirsutism and insulin sensitivity in women with polycystic ovary syndrome.  Hum Reprod. 1998;  13 2706-2711
• 68 Vrbikova J, Stanicka S, Dvorakova K et al.. Metabolic and endocrine effects of treatment with peroral or transdermal oestrogens in conjunction with peroral cyproterone acetate in women with polycystic ovary syndrome.  Eur J Endocrinol. 2004;  150 215-223
• 69 Cagnacci A, Paoletti A M, Renzi A et al.. Glucose metabolism and insulin resistance in women with polycystic ovary syndrome during therapy with oral contraceptives containing cyproterone acetate or desogestrel.  J Clin Endocrinol Metab. 2003;  88 3621-3625
• 70 Morin-Papunen L C, Vauhkonen I, Koivunen R M, Ruokonen A, Martikainen H K, Tapanainen J S. Endocrine and metabolic effects of metformin versus ethinyl estradiol-cyproterone acetate in obese women with polycystic ovary syndrome: a randomized study.  J Clin Endocrinol Metab. 2000;  85 3161-3168
• 71 Armstrong V L, Wiggam M I, Ennis C N et al.. Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate.  QJM. 2001;  94 31-37
• 72 Cibula D, Sindelka G, Hill M, Fanta M, Skrha J, Zivny J. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral contraceptives containing low-androgenic progestin.  Hum Reprod. 2002;  17 76-82
• 73 Elter K, Imir G, Durmusoglu F. Clinical, endocrine and metabolic effects of metformin added to ethinyl estradiol-cyproterone acetate in non-obese women with polycystic ovarian syndrome: a randomized controlled study.  Hum Reprod. 2002;  17 1729-1737
• 74 Morin-Papunen L, Vauhkonen I, Koivunen R, Ruokonen A, Martikainen H, Tapanainen J S. Metformin versus ethinyl estradiol-cyproterone acetate in the treatment of nonobese women with polycystic ovary syndrome: a randomized study.  J Clin Endocrinol Metab. 2003;  88 148-156
• 75 Harborne L, Fleming R, Lyall H, Sattar N, Norman J. Metformin or antiandrogen in the treatment of hirsutism in polycystic ovary syndrome.  J Clin Endocrinol Metab. 2003;  88 4116-4123
• 76 Cibula D, Fanta M, Vrbikova J et al.. The effect of combination therapy with metformin and combined oral contraceptives (COC) versus COC alone on insulin sensitivity, hyperandrogenaemia, SHBG and lipids in PCOS patients.  Hum Reprod. 2005;  20 180-184
• 77 Luque-Ramirez M, Alvarez-Blasco F, Botella-Carretero J I, Martinez-Bermejo E, Lasuncion M A, Escobar-Morreale H F. Comparison of ethinyl-estradiol plus cyproterone acetate versus metformin effects on classic metabolic cardiovascular risk factors in women with the polycystic ovary syndrome.  J Clin Endocrinol Metab. 2007;  92 2453-2461
• 78 Falsetti L, Pasinetti E. Effects of long-term administration of an oral contraceptive containing ethinylestradiol and cyproterone acetate on lipid metabolism in women with polycystic ovary syndrome.  Acta Obstet Gynecol Scand. 1995;  74 56-60
• 79 Pasquali R, Gambineri A, Anconetani B et al.. The natural history of the metabolic syndrome in young women with the polycystic ovary syndrome and the effect of long-term oestrogen-progestagen treatment.  Clin Endocrinol (Oxf). 1999;  50 517-527
• 80 Sharma S T, Nestler J E. Prevention of diabetes and cardiovascular disease in women with PCOS: treatment with insulin sensitizers.  Best Pract Res Clin Endocrinol Metab. 2006;  20 245-260
• 81 Knowler W C, Barrett-Connor E, Fowler S E et al.. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin.  N Engl J Med. 2002;  346 393-403
• 82 Macfarlane D P, Paterson K R, Fisher M. Oral antidiabetic agents as cardiovascular drugs.  Diabetes Obes Metab. 2007;  9 23-30
• 83 Rautio K, Tapanainen J S, Ruokonen A, Morin-Papunen L C. Effects of metformin and ethinyl estradiol-cyproterone acetate on lipid levels in obese and non-obese women with polycystic ovary syndrome.  Eur J Endocrinol. 2005;  152 269-275
• 84 Costello M F, Shrestha B, Eden J, Johnson N P, Sjoblom P. Metformin versus oral contraceptive pill in polycystic ovary syndrome: a Cochrane review.  Hum Reprod. 2007;  22 1200-1209